Product Description
Mechanisms of Action: GnRH Antagonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intramuscular,Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Assertio Holdings
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Prostatic Hyperplasia|Lower Urinary Tract Symptoms|Alzheimer Disease|Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SPI-153-10-1 | P2 |
Completed |
Prostate Cancer |
2014-09-01 |
42% |
| SPI-153-08-1 | P2 |
Terminated |
Lower Urinary Tract Symptoms|Prostatic Hyperplasia |
2010-01-20 |
24% |
| SPI-153-06-1 | P2 |
Completed |
Prostatic Hyperplasia|Lower Urinary Tract Symptoms |
2008-02-27 |
24% |
| 2004-005001-29 | P2 |
Terminated |
Alzheimer Disease |
2007-12-17 |